Trinity Biotech plc (TRIB)
USD 0.81
(-4.35%)
USD 0.81
(-4.35%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 46.49 Million USD | 2.44% |
| 2022 | 32.96 Million USD | 34.47% |
| 2021 | 24.51 Million USD | -13.38% |
| 2020 | 28.29 Million USD | -13.78% |
| 2019 | 32.81 Million USD | -5.6% |
| 2018 | 34.76 Million USD | -4.52% |
| 2017 | 36.41 Million USD | 2.27% |
| 2016 | 35.6 Million USD | 8.56% |
| 2015 | 32.79 Million USD | 1.51% |
| 2014 | 32.3 Million USD | 15.23% |
| 2013 | 28.03 Million USD | 11.76% |
| 2012 | 25.08 Million USD | 3.05% |
| 2011 | 24.34 Million USD | -18.63% |
| 2010 | 29.91 Million USD | -30.29% |
| 2009 | 42.91 Million USD | -70.04% |
| 2008 | 143.24 Million USD | 69.27% |
| 2007 | 84.62 Million USD | 73.25% |
| 2006 | 48.84 Million USD | 20.42% |
| 2005 | 40.56 Million USD | 17.51% |
| 2004 | 34.51 Million USD | 49.22% |
| 2003 | 23.12 Million USD | 20.77% |
| 2002 | 19.15 Million USD | 14.43% |
| 2001 | 16.73 Million USD | 70.8% |
| 2000 | 9.79 Million USD | 23.7% |
| 1999 | 7.92 Million USD | 34.27% |
| 1998 | 5.9 Million USD | 9.26% |
| 1997 | 5.4 Million USD | 125.0% |
| 1996 | 2.4 Million USD | -40.0% |
| 1995 | 4 Million USD | 14.29% |
| 1994 | 3.5 Million USD | -20.45% |
| 1993 | 4.4 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 7.19 Million USD | 21.34% |
| 2024 Q1 | 8.06 Million USD | 6.17% |
| 2023 Q1 | 9.49 Million USD | -13.81% |
| 2023 Q4 | 7.59 Million USD | -13.49% |
| 2023 Q3 | 8.78 Million USD | -3.17% |
| 2023 Q2 | 9.06 Million USD | -4.48% |
| 2023 FY | 33.76 Million USD | 2.44% |
| 2022 Q2 | 8.04 Million USD | 13.32% |
| 2022 Q4 | 11.01 Million USD | 61.65% |
| 2022 FY | 32.96 Million USD | 34.47% |
| 2022 Q1 | 7.09 Million USD | 27.83% |
| 2022 Q3 | 6.81 Million USD | -15.28% |
| 2021 Q4 | 5.55 Million USD | -9.75% |
| 2021 Q1 | 7.83 Million USD | 18.87% |
| 2021 Q3 | 6.15 Million USD | 29.76% |
| 2021 FY | 24.51 Million USD | -13.38% |
| 2021 Q2 | 4.74 Million USD | -39.49% |
| 2020 Q2 | 6.37 Million USD | -16.0% |
| 2020 FY | 28.29 Million USD | -13.78% |
| 2020 Q3 | 7.69 Million USD | 20.74% |
| 2020 Q1 | 7.58 Million USD | -3.15% |
| 2020 Q4 | 6.59 Million USD | -14.3% |
| 2019 FY | 32.81 Million USD | -5.6% |
| 2019 Q2 | 8.23 Million USD | 2.67% |
| 2019 Q1 | 8.01 Million USD | -3.6% |
| 2019 Q4 | 7.83 Million USD | -10.39% |
| 2019 Q3 | 8.73 Million USD | 6.15% |
| 2018 Q1 | 8.62 Million USD | -8.0% |
| 2018 Q3 | 8.74 Million USD | -3.71% |
| 2018 Q4 | 8.31 Million USD | -4.89% |
| 2018 Q2 | 9.08 Million USD | 5.34% |
| 2018 FY | 34.76 Million USD | -4.52% |
| 2017 FY | 36.41 Million USD | 2.27% |
| 2017 Q2 | 8.98 Million USD | 4.71% |
| 2017 Q3 | 9.47 Million USD | 5.37% |
| 2017 Q4 | 9.37 Million USD | -1.03% |
| 2017 Q1 | 8.58 Million USD | -3.41% |
| 2016 Q3 | 8.94 Million USD | -5.4% |
| 2016 FY | 35.6 Million USD | 8.56% |
| 2016 Q2 | 9.46 Million USD | 13.89% |
| 2016 Q1 | 8.3 Million USD | 8.77% |
| 2016 Q4 | 8.88 Million USD | -0.7% |
| 2015 Q1 | 7.76 Million USD | -7.22% |
| 2015 FY | 32.79 Million USD | 1.51% |
| 2015 Q3 | 9.01 Million USD | 7.53% |
| 2015 Q2 | 8.38 Million USD | 7.96% |
| 2015 Q4 | 7.63 Million USD | -15.29% |
| 2014 FY | 32.3 Million USD | 15.23% |
| 2014 Q1 | 7.65 Million USD | -1.71% |
| 2014 Q4 | 8.36 Million USD | 0.01% |
| 2014 Q3 | 8.36 Million USD | 5.71% |
| 2014 Q2 | 7.91 Million USD | 3.38% |
| 2013 Q4 | 7.79 Million USD | 8.34% |
| 2013 Q1 | 6.27 Million USD | 2.13% |
| 2013 FY | 28.03 Million USD | 11.76% |
| 2013 Q3 | 7.19 Million USD | 6.03% |
| 2013 Q2 | 6.78 Million USD | 8.05% |
| 2012 FY | 25.08 Million USD | 3.05% |
| 2012 Q4 | 6.14 Million USD | -3.61% |
| 2012 Q3 | 6.37 Million USD | -1.04% |
| 2012 Q2 | 6.44 Million USD | 0.88% |
| 2012 Q1 | 6.38 Million USD | -10.37% |
| 2011 Q4 | 7.12 Million USD | 15.76% |
| 2011 Q3 | 6.15 Million USD | -3.06% |
| 2011 Q1 | 6.15 Million USD | -6.42% |
| 2011 Q2 | 6.34 Million USD | 3.15% |
| 2011 FY | 24.34 Million USD | -18.63% |
| 2010 Q2 | 8.17 Million USD | -17.03% |
| 2010 Q1 | 9.85 Million USD | -3.47% |
| 2010 Q3 | 6.87 Million USD | -15.95% |
| 2010 Q4 | 6.57 Million USD | -4.28% |
| 2010 FY | 29.91 Million USD | -30.29% |
| 2009 Q1 | 11.27 Million USD | -88.92% |
| 2009 FY | 42.91 Million USD | -70.04% |
| 2009 Q2 | 10.96 Million USD | -2.7% |
| 2009 Q3 | 10.54 Million USD | -3.89% |
| 2009 Q4 | 10.2 Million USD | -3.16% |
| 2008 Q2 | 13.92 Million USD | -0.43% |
| 2008 Q3 | 13.65 Million USD | -1.9% |
| 2008 Q4 | 101.67 Million USD | 644.52% |
| 2008 FY | 143.24 Million USD | 69.27% |
| 2008 Q1 | 13.98 Million USD | 139.73% |
| 2007 Q3 | - USD | -100.0% |
| 2007 Q4 | -35.19 Million USD | 0.0% |
| 2007 Q2 | 14.32 Million USD | 1.75% |
| 2007 Q1 | 14.07 Million USD | -2.84% |
| 2007 FY | 84.62 Million USD | 73.25% |
| 2006 Q2 | 11.08 Million USD | 1.63% |
| 2006 Q1 | 10.9 Million USD | -3.54% |
| 2006 Q3 | 12.37 Million USD | 11.7% |
| 2006 Q4 | 14.48 Million USD | 17.04% |
| 2006 FY | 48.84 Million USD | 20.42% |
| 2005 Q3 | 11 Million USD | 18.48% |
| 2005 Q2 | 9.28 Million USD | 3.59% |
| 2005 Q1 | 8.96 Million USD | -2.34% |
| 2005 FY | 40.56 Million USD | 17.51% |
| 2005 Q4 | 11.3 Million USD | 2.71% |
| 2004 Q4 | 9.18 Million USD | -0.82% |
| 2004 Q1 | 7.16 Million USD | 34.53% |
| 2004 Q2 | 8.91 Million USD | 24.34% |
| 2004 Q3 | 9.25 Million USD | 3.89% |
| 2004 FY | 34.51 Million USD | 49.22% |
| 2003 Q3 | 5.99 Million USD | 4.35% |
| 2003 Q4 | 5.32 Million USD | -11.2% |
| 2003 Q1 | 6.05 Million USD | -3.07% |
| 2003 FY | 23.12 Million USD | 20.77% |
| 2003 Q2 | 5.74 Million USD | -5.04% |
| 2002 FY | 19.15 Million USD | 14.43% |
| 2002 Q2 | 4.09 Million USD | 2.37% |
| 2002 Q3 | 4.8 Million USD | 17.25% |
| 2002 Q1 | 4 Million USD | -39.11% |
| 2002 Q4 | 6.24 Million USD | 29.98% |
| 2001 FY | 16.73 Million USD | 70.8% |
| 2001 Q4 | 6.57 Million USD | 96.49% |
| 2001 Q3 | 3.34 Million USD | -10.15% |
| 2001 Q2 | 3.72 Million USD | 20.36% |
| 2001 Q1 | 3.09 Million USD | -18.65% |
| 2000 Q2 | 2.09 Million USD | 15.65% |
| 2000 Q1 | 1.81 Million USD | -45.37% |
| 2000 Q3 | 2.08 Million USD | -0.76% |
| 2000 FY | 9.79 Million USD | 23.7% |
| 2000 Q4 | 3.8 Million USD | 82.59% |
| 1999 Q2 | 1.6 Million USD | 6.67% |
| 1999 Q4 | 3.32 Million USD | 107.63% |
| 1999 FY | 7.92 Million USD | 34.27% |
| 1999 Q1 | 1.5 Million USD | -28.57% |
| 1999 Q3 | 1.6 Million USD | 0.0% |
| 1998 Q2 | 1.2 Million USD | 0.0% |
| 1998 FY | 5.9 Million USD | 9.26% |
| 1998 Q3 | 1.2 Million USD | 0.0% |
| 1998 Q1 | - USD | 100.0% |
| 1998 Q4 | 2.1 Million USD | 75.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 FY | 5.4 Million USD | 125.0% |
| 1997 Q4 | -16.3 Million USD | 0.0% |
| 1997 Q1 | - USD | 100.0% |
| 1996 Q1 | - USD | 100.0% |
| 1996 Q4 | -7.9 Million USD | 0.0% |
| 1996 Q3 | - USD | 0.0% |
| 1996 FY | 2.4 Million USD | -40.0% |
| 1996 Q2 | - USD | 0.0% |
| 1995 Q2 | - USD | 0.0% |
| 1995 Q3 | - USD | 0.0% |
| 1995 FY | 4 Million USD | 14.29% |
| 1995 Q4 | -11.7 Million USD | 0.0% |
| 1995 Q1 | - USD | 0.0% |
| 1994 Q3 | - USD | 0.0% |
| 1994 FY | 3.5 Million USD | -20.45% |
| 1994 Q2 | - USD | 100.0% |
| 1994 Q1 | -6.6 Million USD | 0.0% |
| 1993 Q4 | - USD | 0.0% |
| 1993 Q2 | - USD | 0.0% |
| 1993 FY | 4.4 Million USD | 0.0% |
| 1993 Q3 | - USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bionano Genomics, Inc. | 148.99 Million USD | 68.794% |
| Prenetics Global Limited | 60.73 Million USD | 23.448% |
| Star Equity Holdings, Inc. | 16.27 Million USD | -185.736% |
| CareDx, Inc | 277.76 Million USD | 83.261% |
| Exact Sciences Corporation | 2.06 Billion USD | 97.744% |
| Exagen Inc. | 52.29 Million USD | 11.088% |
| Inotiv, Inc. | 246.9 Million USD | 81.169% |
| Guardant Health, Inc. | 901.62 Million USD | 94.843% |
| Biodesix, Inc. | 77.41 Million USD | 39.944% |
| BioNexus Gene Lab Corp. | 3.92 Million USD | -1085.164% |
| Precipio, Inc. | 13.63 Million USD | -240.922% |
| iSpecimen Inc. | 16.27 Million USD | -185.644% |
| Natera, Inc. | 938.98 Million USD | 95.048% |
| Aspira Women's Health Inc. | 24.11 Million USD | -92.813% |
| Standard BioTools Inc. | 113.48 Million USD | 59.031% |
| 23andMe Holding Co. | 420.73 Million USD | 88.949% |
| Castle Biosciences, Inc. | 242.78 Million USD | 80.849% |
| Personalis, Inc. | 128.14 Million USD | 63.717% |
| Aclaris Therapeutics, Inc. | 110.52 Million USD | 57.933% |
| Applied DNA Sciences, Inc. | 16.48 Million USD | -182.015% |
| OpGen, Inc. | 30.65 Million USD | -51.657% |
| T2 Biosystems, Inc. | 41.49 Million USD | -12.052% |
| Myriad Genetics, Inc. | 600.1 Million USD | 92.252% |
| ICON Public Limited Company | 755.64 Million USD | 93.847% |
| NeoGenomics, Inc. | 341.25 Million USD | 86.375% |
| Star Equity Holdings, Inc. | 16.27 Million USD | -185.736% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 95.745% |
| RadNet, Inc. | 268.87 Million USD | 82.708% |
| MDxHealth SA | 71.25 Million USD | 34.749% |
| Psychemedics Corporation | 11.33 Million USD | -310.226% |
| Illumina, Inc. | 3.81 Billion USD | 98.781% |
| Check-Cap Ltd. | 19.28 Million USD | -141.069% |
| Twist Bioscience Corporation | 354.18 Million USD | 86.872% |
| DarioHealth Corp. | 62.17 Million USD | 25.217% |
| Fulgent Genetics, Inc. | 171.9 Million USD | 72.953% |
| Sera Prognostics, Inc. | 39.91 Million USD | -16.479% |
| ENDRA Life Sciences Inc. | 10.52 Million USD | -341.937% |
| OPKO Health, Inc. | 574.68 Million USD | 91.909% |
| Medpace Holdings, Inc. | 187.68 Million USD | 75.226% |
| Neogen Corporation | 405.23 Million USD | 88.526% |
| Intelligent Bio Solutions Inc. | 11.7 Million USD | -297.094% |
| Prenetics Global Limited | 60.73 Million USD | 23.448% |
| Mainz Biomed B.V. | 27.15 Million USD | -71.225% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -430.472% |
| Neuronetics, Inc. | 82.25 Million USD | 43.477% |
| Sotera Health Company | 300.46 Million USD | 84.526% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -430.472% |